Teva settles dispute with AstraZeneca over diabetes drug

Teva has settled its patent litigation dispute with AstraZeneca centring on diabetes drug Byetta (exenatide).

The companies have entered a settlement and license agreement that gives Teva permission to manufacture and commercialise a generic version of AstraZeneca’s drug in the US from October next year.

Byetta is an injectable product used to treat type 2 diabetes.

Other terms of the agreem ent have been kept confidential.

In the case, filed in January 2015 at the US District Court the District of Delaware, AstraZeneca accused Teva of infringing seven of its patents protecting Byetta. Teva then filed a counterclaim of non-infringement.

Teva had previously filed for an Abbreviated New Drug Application (ANDA) at the US Food and Drug Administration seeking approval to market a generic version of the drug.

The patents in the case are US numbers; 6,858,576; 6,872,700; 6,956,026; 7,297,761; 6,902,744, 7,521,423 and 7,741,269.